PAHC vs. ABUS, CALT, ALT, IGMS, CMPS, APLT, SLRN, KALV, AVBP, and RDUS
Should you be buying Phibro Animal Health stock or one of its competitors? The main competitors of Phibro Animal Health include Arbutus Biopharma (ABUS), Calliditas Therapeutics AB (publ) (CALT), Altimmune (ALT), IGM Biosciences (IGMS), COMPASS Pathways (CMPS), Applied Therapeutics (APLT), Acelyrin (SLRN), KalVista Pharmaceuticals (KALV), ArriVent BioPharma (AVBP), and Radius Recycling (RDUS).
Phibro Animal Health (NASDAQ:PAHC) and Arbutus Biopharma (NASDAQ:ABUS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, profitability, earnings, dividends, media sentiment, valuation, community ranking, risk and analyst recommendations.
Phibro Animal Health has higher revenue and earnings than Arbutus Biopharma. Arbutus Biopharma is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.
Arbutus Biopharma received 119 more outperform votes than Phibro Animal Health when rated by MarketBeat users. Likewise, 70.78% of users gave Arbutus Biopharma an outperform vote while only 60.04% of users gave Phibro Animal Health an outperform vote.
In the previous week, Phibro Animal Health had 1 more articles in the media than Arbutus Biopharma. MarketBeat recorded 3 mentions for Phibro Animal Health and 2 mentions for Arbutus Biopharma. Phibro Animal Health's average media sentiment score of 0.50 beat Arbutus Biopharma's score of 0.00 indicating that Phibro Animal Health is being referred to more favorably in the media.
Phibro Animal Health has a net margin of 1.51% compared to Arbutus Biopharma's net margin of -401.57%. Phibro Animal Health's return on equity of 16.67% beat Arbutus Biopharma's return on equity.
99.3% of Phibro Animal Health shares are held by institutional investors. Comparatively, 43.8% of Arbutus Biopharma shares are held by institutional investors. 50.1% of Phibro Animal Health shares are held by insiders. Comparatively, 5.4% of Arbutus Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Phibro Animal Health has a beta of 0.75, meaning that its share price is 25% less volatile than the S&P 500. Comparatively, Arbutus Biopharma has a beta of 2.03, meaning that its share price is 103% more volatile than the S&P 500.
Phibro Animal Health presently has a consensus price target of $15.33, indicating a potential upside of 12.66%. Arbutus Biopharma has a consensus price target of $4.33, indicating a potential upside of 57.58%. Given Arbutus Biopharma's stronger consensus rating and higher probable upside, analysts clearly believe Arbutus Biopharma is more favorable than Phibro Animal Health.
Summary
Phibro Animal Health beats Arbutus Biopharma on 11 of the 18 factors compared between the two stocks.
Get Phibro Animal Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for PAHC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PAHC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Phibro Animal Health Competitors List
Related Companies and Tools
